Capreomycin sulfate (Capastat sulfate) CAS:1405-37-4

Capreomycin sulfate (Capastat sulfate) is an essential component in the management of multidrug-resistant tuberculosis (MDR-TB), particularly when standard first-line anti-tuberculosis drugs are ineffective. It is utilized as part of combination therapy regimens to target and treat drug-resistant strains of Mycobacterium tuberculosis. The administration of Capreomycin sulfate involves intramuscular or deep subcutaneous injections, typically under the supervision of healthcare professionals experienced in managing tuberculosis. Treatment with Capreomycin sulfate requires careful monitoring due to potential adverse effects associated with aminoglycoside antibiotics, including kidney toxicity and hearing impairment. Dosage and duration of therapy are individualized based on the patient's condition, weight, renal function, and response to treatment. Patients undergoing Capreomycin sulfate therapy are advised to adhere strictly to the prescribed treatment regimen to maximize its effectiveness and minimize the risk of further drug resistance. Regular monitoring for potential side effects, as well as periodic assessments of kidney function and hearing, are crucial during the course of treatment. Close collaboration with healthcare providers and strict adherence to medical advice are essential for successful tuberculosis management with Capreomycin sulfate, aiming to achieve complete eradication of MDR-TB while minimizing the likelihood of treatment failure or relapse.